Boston Scientific Corporation · NYSE:BSX
Boston Scientific — Guidant — Merger or Acquisition (March 2006)
31 slides from Boston Scientific's merger presentation, Mar 13, 2006
Slide 1: Creating a Global Medical Device Leader
oBoston,. Scientific Boston Scientific Delivering what’s next.’ Creating a Global Medical Device Leader
Slide 2: Safe Harbor: Forward-Looking Statements
Boston Safe tienboorF orward-Looking Statements Scientific This presentation contains “forward-looking statements,” including, among other statements, statements regarding the proposed business combination between Boston Scientific Corporation and Guidant Corporation, and the anticipated consequence
Slide 3: Safe Harbor: Additional Information
Safe barborAdditional Information cBostone Boston Scientific and Guidant have filed a definitive prospectus/joint proxy statement with the SEC in connection with the proposed transaction, The material contained herein is not a substitute for the definitive prospectus/joint proxy statement or any oth
Slide 4: Boston Scientific sales growth history
Boston Scientific $6,283 Boston 1 Scientific Delivering what's next: 0476 sepi9 28 .482673 s1g0t 161 191 “e 200 $018 $2 $3 $8 $19 S16 $22 sar sar $71 $99 $116 9159 bogie Al ae or ao fo "79 "00 “a1 ‘82 ‘03 "4 “5 "86 ‘07 ‘88 “89 ‘90 “91 “92 "99 “94 “95 "96 "97 “9G ‘99 ‘OO “OL ‘02 ‘03 ‘OF ‘05 in miltio
Slide 5: Strategic Build to Date
StrategiowsuildTO" Date gBostone. 90%+ of sales from \_ market leading products... Neuromodulation 2 Endosurge! 20% eS A1% (1 Platform) 2005 Actual Sales
Slide 6: Breadth and Depth of Technology
BreadthsandeBepth of Technology Product Division Franchises Categories Interventional Cardiology 9 39 Endoscopy 1 47 Peripheral 10 28 Urology 12 58 Neurovascular 6 13 Oncology 12 33 Neuromodulation 2 2 Electrophysiology 6 32 Vascular Surgery 6 17 Total 74 270
Slide 7: Worldwide Market Leadership
WorldwidesMerket Leadership Boston, Scientific Interventional Cardiology Interventional / Non Vascular 90%+ of sales from 75%+ of sales from market leading products... market leading products... JNJ = Olympus 5% ~ Source: 2005 & 2004, respectively, company results, analyst reports, MRG reporting Inc
Slide 8: Financial Results
Financial Results Boston, LExeuding: WiWe’Special charges) Se 1€ ntific 10-Year Billions CAGR $7 —— 9 es 19% $5 (Decade of Strategie Bud 20% $4 ra Revenue $2 34% 44% s1 Operating Income $0 Net Income 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Slide 9: Interventional Cardiovascular Market Today
Interventional Cardiovascular Market Today
Slide 10: Interventional Cardiovascular Market: Combination
Interventional Cardiovascular Market Boston, DT Combination Scientific 2005 Worldwide Sales (billions) Boston Scientific SEI Guidant Medtronic Other
Slide 11: DES Market Positions
DES MarketsRositions Boston, GomPetitive Markets (excludes Japan) Scienuf $0.1B S 2002 2003 2004 2005 Industry sources "
Slide 12: DES Market Outlook
DES Market Outlook Boston WallsStF@@t Estimates Scientif Worldwide Sales (Sbillions) $5.6 $5.7 ? $5.2 2005 2006 2007 2008
Slide 13: Diversifying into Microelectronics
Diversifying into Microelectronics...
Slide 14: Neuromodulation Group
Neuromedetation Group ean —»~ | vem @ its $46 ion Microstimulator' a bis
Slide 15: Guidant: The Transforming Event
Guidant: The Transforming Event
Slide 16: Cardiovascular Market Before and After Combination
CardiovasculareMarket Boston BeforssBSC-G mbination Scientific 2005 Worldwide Sales (S billions) Boston Scientific Boston Scientific Medtronic Medtronic JS JS Guidant 10% St. Jude St. Jude 10% Abbott Other 9) Other
Slide 17: Achieving Enhanced Diversification and Higher Growth
Achieving Enhanced,Diversification Boston, andebtigheGrowth ientific Boston Scientific Combined Sales Breakdown Pro Forma Sales Breakdown Neuromodulation Neuromodulation @ crm DES 24% 30% (2 Platforms) (1 Platform) Endosurgery 16%
Slide 18: Key Value Drivers: Acquiring a Leading CRM Business
Key Value DriversieAequitifig’ Leading Business Boston inshligh"fowth CRM Segment Scientific Worldwide Sales (S billions) Forecasted ‘06 — ‘08 CAGR Total 12% ICDs 10% CRT-Ds 23% Pacemakers 3% 2003 2004 2005 2006 2007 2008 m Pacemakers mCRT-Ds mIcDs
Slide 19: Accelerating Growth
Accelerating Growth
Slide 20: Accelerating Revenue Growth
Acceleratinge-Revenue Growth Bostor CAGR > \ 12% to 14%+ 7 Pro Forma — (SinBiions) $17.7 High $15.5 $13.8 . a Low 12.3 S144 $10.6 — $12.8 2007 2008 2009 2010 2011
Slide 21: Accelerating earnings per share growth
Bostor Scientifi “ CAGR- (20% to 21%+ ) Pro Forma 39 High $3.13 Low $2.24 $1.66 $1.98) | $1.52 | 2007 2008 2009 2010 2011 fuer tase ont Bn Safe nt aa Misuse se ne ge Cay.) tan Ate PS pete nb ay 6206 ee me
Slide 22: DES Pipeline
Boston DES Pipeline: Scientific 2005 2006 a a ee © Taxus Express?LV (© TAXUS Liberte on Apex TAXUS NGO TAXUS Barracuda EU/IC (© TAXUS Liberte (© TAXUS Bifurcation © Xience (© Xience on Apex United © TAXUS Liberte (OTAXUS Barracuda States TUS Expres 226140 0 (© TAXUS Liberte LVISV TAXUS NGO © TAXUS L
Slide 23: DES Pipeline: Competitive Products
Boston, Scientific 2005 2006 2007 2008 2009 cata © TAXUS Liberte OTAXUS Barracuda Seterttfi © TAXUS Liberte LVISV TAXUS NGO GUIDANT © TAXUS Liberte on Apex Taxus Express?226140 © TAXUS Bifurcation © © Kience © ience on Apex © Cypher®)2.2614.0 (© Cypher® NXT or NEO Stent P © Endeavor™ Stent’? © Kienc
Slide 24: Strategic Build Continues
Strategic Build Continues Revenue ($M)
Slide 25: Financing the Transaction
Financing the Transaction
Slide 26: Sources of Financing and Transaction Value
(Dollars in bilions) Guidant Purchase Transaction Expenses Total Transaction Value Sources of Financing: Equity to Guidant Shareholders Abbott (net of tax) Bank Loans Available Cash Total
Slide 27: Pro Forma Debt Maturities
ng Debt Maturities ba e $3.5 | $05 ‘040 $0.35 sad $0.25 wll tL 3 8 g g za07 2000 2009 za10 ait 20 a a 20 20 mw m1 019 nm GUS Debt @OUS Debt
Slide 28: Debt Repayment
Boston TDebt Repayment Scientific Pro Forma, in Bitions) Cumulative Debt Maturities $7.6 $3.3 $1.0 ————————— Cumulative Cash Available for Debt Repayment $13.4 $9.8 $4.8 2008 2010 2011
Slide 29: Roadmap to Completing the Transaction
pleting the Transaction sBostor Roadmapstos@ Seientfi M Obtained committed financing M Completed confirmatory due diligence M Definitive merger agreement with Guidant © Definitive divestiture agreement with Abbott ™ Completed rating agency reviews M Submitted HSR & EU anti-trust filings M Proxy fili
Slide 30: ACC Analyst Meeting
Boston Scientific ACC Analyst Meeting March 13% 7:30 a.m. Atlanta
Slide 31: Searchable text section of graphics shown above
Searchable text section of graphics shown above Filed by Boston Scientific Corporation Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company: Guidant Corporation Commission File No.: 333-131608 The foll